MONTREAL, Canada I April 11, 2019 I Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that the Scientific Advisory Group HIV/Viral Diseases (SAG), convened by the Committee for Medicinal Products for Human use (CHMP) in Europe, has given a positive recommendation to Trogarzo® (ibalizumab).

The meeting between the SAG and representatives from Theratechnologies took place this morning in Amsterdam, Netherlands.

“We could not be more pleased with the outcome of today’s meeting. The positive recommendation represents an important step towards the potential approval of Trogarzo® in Europe, which could constitute the second most important market for our product,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc.

A SAG is convened at the request of the CHMP to provide independent recommendations on scientific or technical matters relating to human immunodeficiency virus (HIV) and viral-disease products under evaluation by the CHMP, or on any other scientific issue relevant to the work of the CHMP that relates to this area.

The recommendation from the CHMP to the European Medicines Agency is expected to be announced around May 29, 2019.

About Theratechnologies
Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV. Further information about Theratechnologies is available on the Company’s website at www.theratech.com and on SEDAR at www.sedar.com.

SOURCE: Theratechnologies